CBLO — what changed in the latest 10-Q
A section-by-section comparison of CBLO's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-05-20 vs the prior 10-Q · 2026-02-20
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +66 | −49 | ~34 | 66 |
| Market risk (Item 3) | Text added/removed | +66 | −49 | ~34 | 65 |
| Controls & procedures | Text added/removed | +66 | −49 | ~34 | 65 |
| Legal proceedings | Text added/removed | +66 | −49 | ~34 | 65 |
| Risk factors | Text added/removed | +66 | −49 | ~34 | 65 |
| Other information | Text added/removed | +66 | −49 | ~34 | 64 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-05-20
Preferred stock ($0.001 par value, 20,000,000 shares authorized; 5,000,000 designated as Series A Convertible Preferred Stock (“Series A”) with 4,500,000 and 0 shares of Series A issued and outstanding as of March 31, 2026, and June 30, 2025, respectively) 4,500 -
Gain (loss) on change in fair market value of derivative liability 626,354
Weighted average number of common shares outstanding - Basic and Diluted 448,209,301
Series A Preferred shares issued as compensation - - 4,500,000
Common Shares Par Value Common Shares Additional Paid-in Capital Shares Payable Accumulated Other Comprehensive Income Accumulated Deficit Total
Text removed vs the prior filing · source: 10-Q · 2026-02-20
Three Months Ended December 31, 2024 Six Months Ended December 31, 2025
Gain (loss) on change in fair market value of derivative liability 744,870
Weighted average number of common shares outstanding - Basic and Diluted 408,543,070
Common Shares Par Value Common Shares Additional Paid-in Capital Accumulated Deficit Total
The Company had potentially dilutive instruments outstanding as of December 31, 2025; however, because the Company reported a net loss for the periods presented, the effect of these instruments was anti-dilutive and therefore excluded from diluted earnings (loss) per share.
Market risk (Item 3)
Text added vs the prior filing · source: 10-Q · 2026-05-20
Preferred stock ($0.001 par value, 20,000,000 shares authorized; 5,000,000 designated as Series A Convertible Preferred Stock (“Series A”) with 4,500,000 and 0 shares of Series A issued and outstanding as of March 31, 2026, and June 30, 2025, respectively) 4,500 -
Gain (loss) on change in fair market value of derivative liability 626,354
Weighted average number of common shares outstanding - Basic and Diluted 448,209,301
Series A Preferred shares issued as compensation - - 4,500,000
Common Shares Par Value Common Shares Additional Paid-in Capital Shares Payable Accumulated Other Comprehensive Income Accumulated Deficit Total
Text removed vs the prior filing · source: 10-Q · 2026-02-20
Three Months Ended December 31, 2024 Six Months Ended December 31, 2025
Gain (loss) on change in fair market value of derivative liability 744,870
Weighted average number of common shares outstanding - Basic and Diluted 408,543,070
Common Shares Par Value Common Shares Additional Paid-in Capital Accumulated Deficit Total
The Company had potentially dilutive instruments outstanding as of December 31, 2025; however, because the Company reported a net loss for the periods presented, the effect of these instruments was anti-dilutive and therefore excluded from diluted earnings (loss) per share.
Controls & procedures
Text added vs the prior filing · source: 10-Q · 2026-05-20
Preferred stock ($0.001 par value, 20,000,000 shares authorized; 5,000,000 designated as Series A Convertible Preferred Stock (“Series A”) with 4,500,000 and 0 shares of Series A issued and outstanding as of March 31, 2026, and June 30, 2025, respectively) 4,500 -
Gain (loss) on change in fair market value of derivative liability 626,354
Weighted average number of common shares outstanding - Basic and Diluted 448,209,301
Series A Preferred shares issued as compensation - - 4,500,000
Common Shares Par Value Common Shares Additional Paid-in Capital Shares Payable Accumulated Other Comprehensive Income Accumulated Deficit Total
Text removed vs the prior filing · source: 10-Q · 2026-02-20
Three Months Ended December 31, 2024 Six Months Ended December 31, 2025
Gain (loss) on change in fair market value of derivative liability 744,870
Weighted average number of common shares outstanding - Basic and Diluted 408,543,070
Common Shares Par Value Common Shares Additional Paid-in Capital Accumulated Deficit Total
The Company had potentially dilutive instruments outstanding as of December 31, 2025; however, because the Company reported a net loss for the periods presented, the effect of these instruments was anti-dilutive and therefore excluded from diluted earnings (loss) per share.
Legal proceedings
Text added vs the prior filing · source: 10-Q · 2026-05-20
Preferred stock ($0.001 par value, 20,000,000 shares authorized; 5,000,000 designated as Series A Convertible Preferred Stock (“Series A”) with 4,500,000 and 0 shares of Series A issued and outstanding as of March 31, 2026, and June 30, 2025, respectively) 4,500 -
Gain (loss) on change in fair market value of derivative liability 626,354
Weighted average number of common shares outstanding - Basic and Diluted 448,209,301
Series A Preferred shares issued as compensation - - 4,500,000
Common Shares Par Value Common Shares Additional Paid-in Capital Shares Payable Accumulated Other Comprehensive Income Accumulated Deficit Total
Text removed vs the prior filing · source: 10-Q · 2026-02-20
Three Months Ended December 31, 2024 Six Months Ended December 31, 2025
Gain (loss) on change in fair market value of derivative liability 744,870
Weighted average number of common shares outstanding - Basic and Diluted 408,543,070
Common Shares Par Value Common Shares Additional Paid-in Capital Accumulated Deficit Total
The Company had potentially dilutive instruments outstanding as of December 31, 2025; however, because the Company reported a net loss for the periods presented, the effect of these instruments was anti-dilutive and therefore excluded from diluted earnings (loss) per share.
Risk factors
Text added vs the prior filing · source: 10-Q · 2026-05-20
Preferred stock ($0.001 par value, 20,000,000 shares authorized; 5,000,000 designated as Series A Convertible Preferred Stock (“Series A”) with 4,500,000 and 0 shares of Series A issued and outstanding as of March 31, 2026, and June 30, 2025, respectively) 4,500 -
Gain (loss) on change in fair market value of derivative liability 626,354
Weighted average number of common shares outstanding - Basic and Diluted 448,209,301
Series A Preferred shares issued as compensation - - 4,500,000
Common Shares Par Value Common Shares Additional Paid-in Capital Shares Payable Accumulated Other Comprehensive Income Accumulated Deficit Total
Text removed vs the prior filing · source: 10-Q · 2026-02-20
Three Months Ended December 31, 2024 Six Months Ended December 31, 2025
Gain (loss) on change in fair market value of derivative liability 744,870
Weighted average number of common shares outstanding - Basic and Diluted 408,543,070
Common Shares Par Value Common Shares Additional Paid-in Capital Accumulated Deficit Total
The Company had potentially dilutive instruments outstanding as of December 31, 2025; however, because the Company reported a net loss for the periods presented, the effect of these instruments was anti-dilutive and therefore excluded from diluted earnings (loss) per share.
Other information
Text added vs the prior filing · source: 10-Q · 2026-05-20
Preferred stock ($0.001 par value, 20,000,000 shares authorized; 5,000,000 designated as Series A Convertible Preferred Stock (“Series A”) with 4,500,000 and 0 shares of Series A issued and outstanding as of March 31, 2026, and June 30, 2025, respectively) 4,500 -
Gain (loss) on change in fair market value of derivative liability 626,354
Weighted average number of common shares outstanding - Basic and Diluted 448,209,301
Series A Preferred shares issued as compensation - - 4,500,000
Common Shares Par Value Common Shares Additional Paid-in Capital Shares Payable Accumulated Other Comprehensive Income Accumulated Deficit Total
Text removed vs the prior filing · source: 10-Q · 2026-02-20
Three Months Ended December 31, 2024 Six Months Ended December 31, 2025
Gain (loss) on change in fair market value of derivative liability 744,870
Weighted average number of common shares outstanding - Basic and Diluted 408,543,070
Common Shares Par Value Common Shares Additional Paid-in Capital Accumulated Deficit Total
The Company had potentially dilutive instruments outstanding as of December 31, 2025; however, because the Company reported a net loss for the periods presented, the effect of these instruments was anti-dilutive and therefore excluded from diluted earnings (loss) per share.
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice